BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Higgins GA, Fletcher PJ, Shanahan WR. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacology & Therapeutics 2020;205:107417. [DOI: 10.1016/j.pharmthera.2019.107417] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 St. Onge CM, Taylor KM, Marcus MM, Townsend EA. Sensitivity of a fentanyl-vs.-social interaction choice procedure to environmental and pharmacological manipulations. Pharmacology Biochemistry and Behavior 2022;221:173473. [DOI: 10.1016/j.pbb.2022.173473] [Reference Citation Analysis]
2 Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia 2022. [PMID: 35950617 DOI: 10.1111/epi.17376] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cai Y, Li X, Zhou H, Zhou J. The serotonergic system dysfunction in diabetes mellitus. Front Cell Neurosci 2022;16:899069. [DOI: 10.3389/fncel.2022.899069] [Reference Citation Analysis]
4 Huang J, Pham M, Panenka WJ, Honer WG, Barr AM. Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity. Front Psychiatry 2022;13:891512. [DOI: 10.3389/fpsyt.2022.891512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Le Foll B, Piper ME, Fowler CD, Tonstad S, Bierut L, Lu L, Jha P, Hall WD. Tobacco and nicotine use. Nat Rev Dis Primers 2022;8:19. [PMID: 35332148 DOI: 10.1038/s41572-022-00346-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Bialer M, Perucca E. Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? CNS Drugs. [DOI: 10.1007/s40263-022-00896-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Baumann CW, Clark BC, Phillips BE, Szewczyk NJ, Consitt LA. Regenerative Rehabilitation in Sarcopenia, Dynapenia, and Frailty. Physiology in Health and Disease 2022. [DOI: 10.1007/978-3-030-95884-8_5] [Reference Citation Analysis]
8 Anisman H, Kusnecov AW. Eating and nutrition links to cancer. Cancer 2022. [DOI: 10.1016/b978-0-323-91904-3.00008-2] [Reference Citation Analysis]
9 Banks ML. Environmental influence on the preclinical evaluation of substance use disorder therapeutics. Behavioral Pharmacology of Drug Abuse: Current Status 2022. [DOI: 10.1016/bs.apha.2021.10.004] [Reference Citation Analysis]
10 Yang Y, Zhao B, Gao X, Sun J, Ye J, Li J, Cao P. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. J Exp Clin Cancer Res 2021;40:331. [PMID: 34686205 DOI: 10.1186/s13046-021-02141-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
11 Pejčić A, Janković SM, Đešević M, Gojak R, Lukić S, Marković N, Milosavljević M. Novel and emerging therapeutics for genetic epilepsies. Expert Rev Neurother 2021;21:1283-301. [PMID: 34633254 DOI: 10.1080/14737175.2021.1992275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tabbara RI, Li Z, Fletcher PJ, Lê AD. The serotonin 2C receptor agonist lorcaserin, alone and in combination with the opioid receptor antagonist naltrexone, attenuates binge-like ethanol drinking. Addict Biol 2021;26:e13040. [PMID: 33928736 DOI: 10.1111/adb.13040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Negus SS, Banks ML. Confronting the challenge of failed translation in medications development for substance use disorders. Pharmacol Biochem Behav 2021;210:173264. [PMID: 34461148 DOI: 10.1016/j.pbb.2021.173264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li Y, Tao Y, Gao X, Yu F. Case Report: Bilateral Ciliary Body Detachment in a Patient Taking Oral Diet Pills. Optom Vis Sci 2021;98:876-80. [PMID: 34460449 DOI: 10.1097/OPX.0000000000001743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Santos GM, Ikeda J, Coffin P, Walker JE, Matheson T, McLaughlin M, Jain J, Vittinghoff E, Batki SL. Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. PLoS One 2021;16:e0254724. [PMID: 34265007 DOI: 10.1371/journal.pone.0254724] [Reference Citation Analysis]
16 Saraf TS, Felsing DE, Armstrong JL, Booth RG, Canal CE. Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice. Epilepsy Res 2021;175:106677. [PMID: 34130255 DOI: 10.1016/j.eplepsyres.2021.106677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Serafine KM, O'Dell LE, Zorrilla EP. Converging vulnerability factors for compulsive food and drug use. Neuropharmacology 2021;196:108556. [PMID: 33862029 DOI: 10.1016/j.neuropharm.2021.108556] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 De Deurwaerdère P, Chagraoui A, Di Giovanni G. Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. Prog Brain Res 2021;261:161-264. [PMID: 33785130 DOI: 10.1016/bs.pbr.2021.02.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Paderina DZ, Boiko AS, Pozhidaev IV, Bocharova AV, Mednova IA, Fedorenko OY, Kornetova EG, Loonen AJM, Semke AV, Bokhan NA, Ivanova SA. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. J Pers Med 2021;11:181. [PMID: 33807811 DOI: 10.3390/jpm11030181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
20 Park S, Kim Y, Lee J, Lee JY, Kim H, Lee S, Oh CM. A Systems Biology Approach to Investigating the Interaction between Serotonin Synthesis by Tryptophan Hydroxylase and the Metabolic Homeostasis. Int J Mol Sci 2021;22:2452. [PMID: 33671067 DOI: 10.3390/ijms22052452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Johannessen Landmark C, Potschka H, Auvin S, Wilmshurst JM, Johannessen SI, Kasteleijn-Nolst Trenité D, Wirrell EC. The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results. Epilepsia 2021;62:857-73. [PMID: 33638459 DOI: 10.1111/epi.16849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
22 Che X, Cai J, Liu Y, Xu T, Yang J, Wu C. Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges. Pharmacol Ther 2021;223:107820. [PMID: 33600854 DOI: 10.1016/j.pharmthera.2021.107820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
23 Higgins GA, Sellers EM. 5-HT(2A) and 5-HT(2C) receptors as potential targets for the treatment of nicotine use and dependence. Prog Brain Res 2021;259:229-63. [PMID: 33541678 DOI: 10.1016/bs.pbr.2021.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 2021;73:310-520. [PMID: 33370241 DOI: 10.1124/pr.118.015552] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 30.5] [Reference Citation Analysis]
25 De Deurwaerdère P, Chagraoui A, Cunningham KA. Editorial: Contemporary Perspective on 5-HT2C Receptor Function and Its Pharmacological Targeting. Front Pharmacol 2020;11:606414. [PMID: 33324228 DOI: 10.3389/fphar.2020.606414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Briand F, Brousseau E, Maupoint J, Dubroca C, Costard C, Breyner N, Burcelin R, Sulpice T. Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model. European Journal of Pharmacology 2020;882:173316. [DOI: 10.1016/j.ejphar.2020.173316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Di Giovanni G, Bharatiya R, Puginier E, Ramos M, De Deurwaerdère S, Chagraoui A, De Deurwaerdère P. Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain. Front Pharmacol 2020;11:962. [PMID: 32714188 DOI: 10.3389/fphar.2020.00962] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
28 Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology 2020;177:108155. [PMID: 32522572 DOI: 10.1016/j.neuropharm.2020.108155] [Cited by in Crossref: 53] [Cited by in F6Publishing: 30] [Article Influence: 26.5] [Reference Citation Analysis]
29 Tong J, Meyer JH, Boileau I, Ang LC, Fletcher PJ, Furukawa Y, Kish SJ. Serotonin transporter protein in autopsied brain of chronic users of cocaine. Psychopharmacology (Berl) 2020;237:2661-71. [PMID: 32494974 DOI: 10.1007/s00213-020-05562-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
30 Cavaletti G, Marmiroli P. Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers (Basel) 2020;12:E1370. [PMID: 32471028 DOI: 10.3390/cancers12061370] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
31 Anastasio NC, Sholler DJ, Fox RG, Stutz SJ, Merritt CR, Bjork JM, Moeller FG, Cunningham KA. Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration. Neuropharmacology 2020;168:108009. [DOI: 10.1016/j.neuropharm.2020.108009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
32 Higgins GA, Brown M, St John J, MacMillan C, Silenieks LB, Thevarkunnel S. Effects of 5-HT2C receptor modulation and the NA reuptake inhibitor atomoxetine in tests of compulsive and impulsive behaviour. Neuropharmacology 2020;170:108064. [PMID: 32222404 DOI: 10.1016/j.neuropharm.2020.108064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
33 Bacqué-Cazenave J, Bharatiya R, Barrière G, Delbecque JP, Bouguiyoud N, Di Giovanni G, Cattaert D, De Deurwaerdère P. Serotonin in Animal Cognition and Behavior. Int J Mol Sci 2020;21:E1649. [PMID: 32121267 DOI: 10.3390/ijms21051649] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 40.0] [Reference Citation Analysis]
34 Brandt L, Jones JD, Martinez S, Manubay JM, Mogali S, Ramey T, Levin FR, Comer SD. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug Alcohol Depend 2020;208:107859. [PMID: 31980285 DOI: 10.1016/j.drugalcdep.2020.107859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]